Onkológia 3/2022

Updated ESMO recommendations for the treatment of newly diagnosed ovarian epithelial carcinoma

Maintenance treatment with PARP inhibitors has become standard practice in the management of a specific group of patients with recurrent ovarian cancer. Findings from clinical trials of maintenance treatment with PARP inhibitors in the treatment of newly diagnosed ovarian cancer have expanded the use of PARP inhibitors to this group of patients. In addition, the results were so convincing that the ESMO recommendations were updated in a relatively short time regarding the need to test the mutational status of patients and the need for maintenance treatment. In this article, we present a summary of the recommendations and the main results of the clinical studies that formed the basis for the mentioned update.

Keywords: ovarian cancer, ESMO guidelines, PARP inhibitors